Diabetes Mellitus
Conditions
Keywords
diabetes mellitus, type 2 diabetes, supplements, genetics, berberine, HbA1c
Brief summary
This pilot, genotype-stratified clinical trial aims to investigate the safety and preliminary efficacy of berberine supplementation in adult patients with type 2 diabetes mellitus (T2DM) who carry a specific high-risk TCF7L2 polymorphism (e.g., rs7903146) in the homozygous state. The study will compare improvements in glycemic control and metabolic markers between two groups: (1) homozygous carriers of the TCF7L2 unfavorable variant and (2) non-carriers (wild-type). It is hypothesized that berberine will yield greater reductions in HbA1c and fasting plasma glucose among homozygous carriers, potentially due to their distinct TCF7L2-mediated insulin secretion and sensitivity pathways.
Detailed description
Type 2 diabetes mellitus is driven by a combination of insulin resistance and impaired insulin secretion. Genetic polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene have been strongly associated with an increased risk of T2DM, potentially through altered beta-cell function and incretin signaling. Berberine, a natural alkaloid derived from plants such as Coptis chinensis, has demonstrated hypoglycemic effects by modulating pathways like AMPK, thereby improving insulin sensitivity and glucose metabolism. This pilot trial aims to clarify whether berberine offers a more pronounced metabolic benefit to individuals homozygous for a high-risk TCF7L2 polymorphism by targeting their unique pathophysiological mechanisms. Results will inform future larger-scale, genotype-focused interventional trials.
Interventions
DIETARY_SUPPLEMENTBerberine
Berberine 500-1000 mg, administered 2-3 times per day for 12 weeks, in addition to standard of care
Sponsors
Center for New Medical Technologies, Novosibirsk, Russia
S.LAB (SOLOWAYS)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Adults (age 30-70 years) with a confirmed diagnosis of type 2 diabetes mellitus. * On stable doses of metformin or other standard oral antihyperglycemic agents for at least 4 weeks prior to enrollment. * Willingness to undergo genetic testing for TCF7L2 polymorphisms. For the Homozygous Variant Cohort: confirmed homozygous high-risk TCF7L2 polymorphism (e.g., rs7903146) prior to enrollment. * For the Non-Variant Cohort: confirmed wild-type TCF7L2 genotype.
Exclusion criteria
* Current use of insulin therapy or recent (within 4 weeks) change in diabetic medications. Known hypersensitivity or intolerance to berberine or related compounds. * Significant renal or hepatic impairment. * Pregnancy or breastfeeding. * Any other acute or chronic condition that, in the investigator's judgment, could compromise the patient's safety or the study's integrity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Glycated Hemoglobin (HbA1c) | 12 weeks |
| Change in Fasting Plasma Glucose (FPG) | 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Lipid Profile Triglyceride | 12 weeks | — |
| Change in Lipid Profile LDL-C | 12 weeks | — |
| Change in HOMA-IR (Insulin Resistance Index) | 12 weeks | — |
| Change in Body Weight or Body Mass Index (BMI) | 12 weeks | — |
| Change in Patient-Reported Quality of Life as Measured by the World Health Organization | 12 weeks | Patient-reported quality of life will be assessed using the World Health Organization Quality of Life Instrument, Short Form (WHOQOL-BREF). This validated questionnaire provides scores ranging from 0 to 100 for each domain (physical health, psychological health, social relationships, and environment), where higher scores indicate a better quality of life. The outcome will be reported as the mean change in the relevant domain scores from baseline to 12 weeks. |
| Change in Lipid Profile HDL-C | 12 weeks | — |
| Number of Adverse Events | 12 weeks | — |
Countries
Russia
Outcome results
None listed